Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”

• Ottavio Secchi,
• Andrea Franchi,
• Armando Lunello

Affiliations

Ottavio Secchi

Health Economics Market Access Reimbursement Manager, Janssen Italy, Cologno Monzese (MI) - Italy

Andrea Franchi

Health Economics Market Access Reimbursement Team Leader, Janssen Italy, Cologno Monzese (MI) - Italy

Armando Lunello

Medical Affairs Manager, Janssen Italy, Cologno Monzese (MI) - Italy